For the Inventor, By the Inventor

Enter assignee name

Rockville, MD, United States of America

Macrogenics, Inc.

USPTO Granted Patents = 133

% Expired Patents = 25.6

CIPO Patents = 20

EPO Patents = 42

Trademarks = 6

Forward Citations = 2,219

Loading Chart...

Loading Chart...

66 inventors (with patents filed for the assignee):

Leslie Sydnor Johnson (91 out of 128 patents)

Ling Ling Huang (61 out of 64 patents)

Ezio Bonvini (42 out of 43 patents)

4. Scott Koenig (34 out of 58 patents)

5. Paul A Moore (34 out of 81 patents)

6. Kalpana Shah (20 out of 20 patents)

7. Nadine Tuaillon (18 out of 18 patents)

8. Jeffrey B Stavenhagen (14 out of 15 patents)

9. Deryk T Loo (13 out of 17 patents)

10. Liqin Liu (12 out of 12 patents)

11. Ross La Motte-Mohs (11 out of 11 patents)

12. Chia-Ying Kao Lam (11 out of 12 patents)

13. Christopher Rankin (11 out of 11 patents)

14. Francine Zhifen Chen (10 out of 14 patents)

15. Sergey Gorlatov (9 out of 9 patents)

Core Competencies:

PD-1 Binding

Bispecific Molecules

HER2/neu Antibodies

LAG-3 Binding

CD3 Binding

Tri-Specific Binding

Antibody Drug Conjugates

Combination Therapy

Covalent Diabodies

B7-H3 Antibodies

IL-23A Targeting

Fc Region Alterations

133 patents: Sort by Forward Citations

1. 12760106 - Covalent Diabodies and Uses Thereof (2026-10-13),

2. 12600779 - LAG-3-Binding Molecules and Methods of Use Thereof (2026-04-14),

3. 12534531 - PD-1-BINDING MOLECULES AND METHODS OF USE THEREOF (2026-01-27),

4. 12448448 - Anti-PD-1 antibodies and uses thereof (2025-10-21),

5. 12435155 - CD137 binding molecules and uses thereof (2025-10-07),

6. 12364756 - Pharmaceutical compositions of a PD-1 antibody and use of the same (2025-07-22),

7. 12173051 - Bispecific molecules comprising an HIV-1 envelope targeting arm (2024-12-24),

8. 12049501 - CD3-binding molecules capable of binding to human and non-human CD3 (2024-07-30),

9. 12024569 - HER2/neu-specific antibodies and methods of using same (2024-07-02),

10. 11942149 - Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof (2024-03-26),

11. 11884744 - Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof (2024-01-30),

12. 11858991 - LAG-3-binding molecules and methods of use thereof (2024-01-02),

13. 11840571 - Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4 (2023-12-12),

14. 11820818 - Multi-chain polypeptide-containing tri-specific binding molecules (2023-11-21),

15. 11795226 - Bispecific CD16-binding molecules and their use in the treatment of disease (2023-10-24),

Company Overview

Macrogenics, Inc., based in Rockville, MD, specializes in the development of innovative immunotherapy molecules aimed at treating cancer. The company focuses on advanced therapeutic modalities, including PD-1 binding, bispecific molecules, and antibody drug conjugates. Macrogenics is dedicated to enhancing treatment efficacy through combination therapies and has a strong emphasis on targeting specific cancer antigens such as HER2/neu. Their research encompasses a range of binding technologies, including LAG-3 and CD3, positioning them at the forefront of cancer immunotherapy advancements.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

133 Patents

#3 in Rockville, MD

#24 in Maryland

#2,915 in US

#6,059 in the World

Rockville, MD, United States of America

Macrogenics, Inc.

Forward Citations = 2,219

66 inventors:

Leslie Sydnor Johnson (91 out of 128 patents)

Ling Ling Huang (61 out of 64 patents)

Ezio Bonvini (42 out of 43 patents)

4. Scott Koenig (34 out of 58 patents)

5. Paul A Moore (34 out of 81 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Macrogenics, Inc.. Retrieved from https://idiyas.com/company/macrogenics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…